Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

Overview

cited authors

Kim, Dong-Wan; Gadgeel, Shirish; Gettinger, Scott N.; Riely, Gregory J.; Oxnard, Geoffrey R.; Mekhail, Tarek; Schmid, Peter; Dowlati, Afshin; Heist, Rebecca S.; Wozniak, Antoinette J.; Singh, Jatinder; Cha, Edward; Spahn, Jessica; Ignatius, Sai-Hong

authors

Mekhail, Tarek M., MD

Publication Date

August 1, 2022

webpage

Web of Science

published in

JTO CLINICAL AND RESEARCH REPORTS Journal

Research

keywords

ALK-positive
Alectinib
Atezolizumab
Non-small cell lung cancer
Phase 1b study

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.